Proteogenomic profiling of high-grade B-cell lymphoma with 11q aberrations and Burkitt lymphoma reveals lymphoid enhancer binding factor 1 as a novel biomarker Journal Article
| Authors: | Hurwitz, S. N.; Lockhart, B.; Önder, Ö.; Wu, R.; Sethi, S.; Aypar, U.; Siebert, R.; Dogan, A.; Pillai, V.; Elenitoba-Johnson, K. S. J.; Lim, M. S. |
| Article Title: | Proteogenomic profiling of high-grade B-cell lymphoma with 11q aberrations and Burkitt lymphoma reveals lymphoid enhancer binding factor 1 as a novel biomarker |
| Abstract: | High-grade B-cell lymphomas with 11q aberrations (HGBL-11q) represent a World Health Organization-defined group of lymphomas that harbor recurrent chromosome 11q aberrations involving proximal gains and telomeric losses. Although a limited number of HGBL-11q cases evaluated thus far appear to show a similar course and prognosis as Burkitt lymphoma (BL), many molecular differences have been appreciated, most notably the absence of MYC rearrangement. Despite biological differences between BL and HGBL-11q, histomorphologic and immunophenotypic distinction remains challenging. Here, we provide a comparative whole proteomic profile of BL- and HGBL-11q-derived cell lines, identifying numerous shared and differentially expressed proteins. Transcriptome profiling performed on paraffin-embedded tissue samples from primary BL and HGBL-11q lymphomas was additionally performed to provide further molecular characterization. Overlap of proteomic and transcriptomic data sets identified several potential novel biomarkers of HGBL-11q, including diminished lymphoid enhancer-binding factor 1 expression, which was validated by immunohistochemistry staining in a cohort of 23 cases. Altogether, these findings provide a comprehensive multimodal and comparative molecular profiling of BL and HGBL-11q and suggest the use of enhancer-binding factor 1 as an immunohistochemistry target to distinguish between these aggressive lymphomas. (c) 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved. |
| Keywords: | mass spectrometry; gene; biomarker; overexpression; b-cell lymphoma; subset; transcriptomic; 11q aberration; computational platform |
| Journal Title: | Modern Pathology |
| Volume: | 36 |
| Issue: | 7 |
| ISSN: | 0893-3952 |
| Publisher: | Nature Research |
| Date Published: | 2023-07-01 |
| Start Page: | 100170 |
| Language: | English |
| ACCESSION: | WOS:000983281200001 |
| DOI: | 10.1016/j.modpat.2023.100170 |
| PROVIDER: | wos |
| PUBMED: | 36997001 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work